Brief: Abbisko Cayman Says Oral Pd-L1 Inhibitor Received Clinical Trial Approval From Nmpa Of People's Republic Of China
01/04/2022 03:15
April 1 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* ORAL PD-L1 INHIBITOR RECEIVED CLINICAL TRIAL APPROVAL FROM
NMPA
OF PEOPLE'S REPUBLIC OF CHINA
Source text for Eikon: ID:
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration